Your browser is no longer supported. Please, upgrade your browser.
Settings
ALKS Alkermes plc daily Stock Chart
ALKS [NASD]
Alkermes plc
Index- P/E- EPS (ttm)-0.25 Insider Own0.80% Shs Outstand148.63M Perf Week-2.90%
Market Cap9.49B Forward P/E- EPS next Y-0.25 Insider Trans-33.61% Shs Float147.71M Perf Month4.93%
Income-36.40M PEG- EPS next Q-0.08 Inst Own98.10% Short Float5.32% Perf Quarter6.24%
Sales649.80M P/S14.60 EPS this Y-275.00% Inst Trans-0.05% Short Ratio7.05 Perf Half Y9.62%
Book/sh9.59 P/B6.66 EPS next Y43.20% ROA-1.90% Target Price70.82 Perf Year25.25%
Cash/sh5.03 P/C12.69 EPS next 5Y34.50% ROE-2.70% 52W Range38.49 - 75.17 Perf YTD9.02%
Dividend- P/FCF- EPS past 5Y12.90% ROI-5.90% 52W High-15.07% Beta1.15
Dividend %- Quick Ratio8.40 Sales past 5Y28.30% Gross Margin72.80% 52W Low65.86% ATR2.20
Employees1300 Current Ratio8.80 Sales Q/Q23.80% Oper. Margin-15.20% RSI (14)54.61 Volatility3.41% 3.71%
OptionableYes Debt/Eq0.25 EPS Q/Q-23.50% Profit Margin-5.60% Rel Volume0.64 Prev Close63.07
ShortableYes LT Debt/Eq0.25 EarningsJul 30 BMO Payout- Avg Volume1.12M Price63.84
Recom2.30 SMA201.30% SMA504.71% SMA2007.68% Volume716,365 Change1.22%
Jun-09-15Initiated Guggenheim Neutral
May-21-15Initiated Barclays Overweight $74
Jan-08-15Reiterated Mizuho Buy $72 → $81
Jul-31-14Reiterated Mizuho Buy $61 → $59
Apr-10-14Upgrade Mizuho Neutral → Buy $55 → $61
Apr-09-14Reiterated MKM Partners Sell $32 → $35
Feb-28-14Reiterated UBS Neutral $42 → $53
Feb-28-14Reiterated MKM Partners Sell $26 → $32
Feb-28-14Reiterated Mizuho Neutral $33 → $56
Dec-05-13Downgrade UBS Buy → Neutral $37 → $42
Nov-01-13Reiterated Mizuho Neutral $30 → $33
Oct-30-13Initiated FBR Capital Mkt Perform $31
May-24-13Reiterated UBS Buy $32 → $37
May-24-13Downgrade MKM Partners Neutral → Sell
Apr-18-13Downgrade Mizuho Buy → Neutral $30 → $26
Apr-17-13Reiterated MKM Partners Neutral $23 → $25
Jan-23-13Downgrade MKM Partners Buy → Neutral
Nov-16-12Initiated Mizuho Buy $27
Jan-25-12Upgrade MKM Partners Neutral → Buy $19 → $20
Aug-23-11Upgrade UBS Neutral → Buy $20.50 → $21
Jul-01-15 12:09PM  Wall Street Is Running Out Of Ways To Make Easy Money Off Corporate Tax Loopholes at Forbes
08:09AM  Wall Street Is Running Out Of Ways To Make Easy Money Off Corporate Tax Loopholes
Jun-24-15 02:02AM  Edited Transcript of ALKS conference call or presentation 23-Jun-15 12:00pm GMT
Jun-23-15 08:00AM  Alkermes Plc Conference Call to Discuss Data of ALKS 3831 for Treatment of Schizophrenia scheduled for 8:00 am ET today
Jun-19-15 06:00PM  The CEO who quit cigarettes for his stock's health
Jun-18-15 06:00AM  Jim Cramer's Top Takeaways: Palo Alto Networks, Tesla, Ambarella, Allergan, Wingstop, Alkermes at TheStreet
Jun-17-15 08:43PM  Jim Cramer's 'Mad Money' Recap: Thanks for Nothing, Janet Yellen at TheStreet
07:20PM  Cramer Remix: Are you smarter than Janet Yellen? at CNBC
04:30PM  Biomarin Pharmaceutical Inc to Discuss Phase 2 Results with BMN 111 Call scheduled for 4:30 pm ET today
08:37AM  Alkermes (ALKS) in Focus: Stock Rises 10.1% in Session - Tale of the Tape
Jun-16-15 11:52AM  Alkermes (ALKS) Stock Gains After Announcing Presentation at Annual ASCP Meeting at TheStreet +10.12%
07:00AM  Alkermes to Present Data From Late-Stage CNS Portfolio at Upcoming American Society of Clinical Psychopharmacology Annual Meeting Business Wire
Jun-09-15 04:00PM  Aripiprazole Lauroxil Phase 3 Schizophrenia Study Results Published in Journal of Clinical Psychiatry Business Wire
08:47AM  Coverage initiated on Alkermes by Guggenheim
Jun-02-15 04:00PM  Alkermes Corporate Presentation to be Webcast At The Goldman Sachs 36th Annual Global Healthcare Conference Business Wire
May-29-15 05:01PM  ALKERMES PLC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Secur
07:00AM  Alkermes to Present Clinical Data on ALKS 8700 at Annual Meeting of the Consortium of Multiple Sclerosis Centers Business Wire
May-26-15 04:00PM  Alkermes Corporate Presentation to be Webcast at the Jefferies 2015 Global Healthcare Conference Business Wire
09:30AM  The Zacks Analyst Blog Highlights: Johnson & Johnson, AstraZeneca, ACADIA Pharmaceuticals, Actavis and Alkermes - Press Releases
May-21-15 02:19PM  Biotech: Don't Bet Against Small Caps Just Yet at Barrons.com
09:00AM  4 SMID-Cap Biotechs Barclays Just Confessed It Loves
May-14-15 04:26PM  Top New Picks of Healthcare Fund Blue Jay Capital: Endo International plc (ENDP), Alkermes Plc (ALKS), Akorn Inc. (AKRX) at Insider Monkey
May-12-15 09:00AM  Top Analyst Upgrades and Downgrades: Alkermes, Cisco, Gap, Rackspace, SouFun, Verizon and More at 24/7 Wall St.
May-11-15 04:12PM  Alkermes Corporate Presentation to be Webcast at the UBS Global Healthcare Conference Business Wire
May-08-15 11:10AM  Best U.S. Pharma Picks, Big and Small at Barrons.com
May-06-15 01:04PM  ALKERMES PLC. Financials
May-04-15 03:35PM  Alkermes' Q1 Loss Narrower than Expected, Maintains View - Analyst Blog
May-01-15 06:02PM  Alkermes (ALKS) Earnings Report: Q1 2015 Conference Call Transcript at TheStreet +6.74%
02:35PM  Biotech execs remember MIT professor: He inspired so many scientists at bizjournals.com
Apr-30-15 08:46AM  Alkermes reports 1Q loss
08:30AM  Alkermes Plc Earnings Call scheduled for 8:30 am ET today
07:12AM  Alkermes plc Reports First Quarter 2015 Financial Results at noodls
07:07AM  Q1 2015 Alkermes Plc Earnings Release - Before Market Open
07:06AM  ALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:00AM  Alkermes plc Reports First Quarter 2015 Financial Results Business Wire
Apr-28-15 01:33PM  5 Biotech Stocks to Avoid After Monday's Slump - Analyst Blog
Apr-23-15 04:05PM  Alkermes to Host Conference Call to Discuss First Quarter 2015 Financial Results at noodls
04:00PM  Alkermes to Host Conference Call to Discuss First Quarter 2015 Financial Results Business Wire
Apr-16-15 04:31PM  ALKERMES PLC. Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Apr-13-15 07:16AM  ALKERMES PLC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
07:03AM  Alkermes to Present Preclinical Data on Novel Selective Effector Cell Activator (SECA) Immuno-Oncology Candidate at Upcoming American Association for Cancer Research Annual Meeting at noodls
07:00AM  Alkermes to Present Preclinical Data on Novel Selective Effector Cell Activator (SECA) Immuno-Oncology Candidate at Upcoming American Association for Cancer Research Annual Meeting Business Wire
Apr-09-15 09:30AM  The Zacks Analyst Blog Highlights: Alkermes, Regulus, Juno Therapeutics, Targacept and Gilead - Press Releases
Apr-07-15 06:08PM  Alkermes Reports Encouraging Data on Schizophrenia Drug - Analyst Blog
Apr-06-15 07:04AM  Alkermes Announces Positive Topline Results from Complete Six-Month Phase 2 Clinical Trial of ALKS 3831 in Schizophrenia at noodls
07:00AM  Alkermes Announces Positive Topline Results from Complete Six-Month Phase 2 Clinical Trial of ALKS 3831 in Schizophrenia Business Wire
Mar-30-15 06:09PM  Biogen/AbbVie's MS Drug Zinbryta Under Review in the EU - Analyst Blog
Mar-27-15 12:14PM  Alkermes 'Taking A Pause,' Citi Says
Mar-23-15 05:47PM  Alkermes plc -- Moody's affirms Alkermes' Ba3 ratings; changes outlook to stable at Moody's
07:04AM  Alkermes to Present Data on Aripiprazole Lauroxil and ALKS 3831 at 15th International Congress on Schizophrenia Research at noodls
07:00AM  Alkermes to Present Data on Aripiprazole Lauroxil and ALKS 3831 at 15th International Congress on Schizophrenia Research Business Wire
Mar-12-15 08:13AM  Analysts' Actions: Alkermes, GNC, Hewlett-Packard and More
Mar-10-15 04:10PM  Alkermes Streamlines Operations, Revises 2015 Guidance - Analyst Blog
Mar-09-15 06:40AM  Alkermes to Sell Plant to Recro Pharma at The Wall Street Journal
06:10AM  Alkermes plc Announces Sale of Gainesville, GA Manufacturing Facility to Recro Pharma, Inc. at noodls
06:07AM  ALKERMES PLC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Office
06:00AM  Alkermes plc Announces Sale of Gainesville, GA Manufacturing Facility to Recro Pharma, Inc. Business Wire
Mar-04-15 06:25PM  Cramer: Best of biotech
Mar-03-15 05:00PM  Alkermes Intends to Add New Candidate to its Pipeline - Analyst Blog
04:00PM  Alkermes Corporate Presentation to be Webcast at the Barclays Global Healthcare Conference Business Wire
Mar-02-15 07:00AM  Alkermes Announces New Drug Candidate, ALKS 7119, for Treatment of Alzheimers Agitation, Depression and Other CNS Diseases Business Wire
Feb-26-15 11:07AM  Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blog Zacks
Feb-25-15 09:32AM  Alkermes Falls on Pipeline News; Q4 Earnings Plunge Y/Y - Analyst Blog Zacks
Feb-24-15 04:00PM  Alkermes Corporate Presentation to be Webcast at the Cowen and Company 35th Annual Health Care Conference Business Wire
12:55PM  Alkermes shares down after it stops development of pain pill at bizjournals.com
11:58AM  Alkermes beats Street 4Q forecasts AP
11:18AM  Jim Cramer: Use Share Weakness to Buy Alkermes for Its Drug Pipeline at TheStreet
10:21AM  Waiting for Yellen Q&A, but QE helping elsewhere at CNBC
08:30AM  Alkermes Plc Earnings Call scheduled for 8:30 am ET today CCBN
07:54AM  Alkermes To Discontinue Development of Pain Treatment at The Wall Street Journal
07:07AM  ALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
07:07AM  Q4 2014 Alkermes Plc Earnings Release - Before Market Open CCBN
07:01AM  Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2014 and Provides Financial Expectations for 2015 Business Wire
07:00AM  Alkermes Announces Results From Phase 1 Study of ALKS 7106 Business Wire
Feb-23-15 04:00PM  Alkermes Announces Webcast of Analyst and Investor Event on March 2, 2015 Business Wire
07:00AM  Alkermes Appoints Mark Namchuk, Ph.D., As Senior Vice President of Research, Pharmaceutical and Nonclinical Development Business Wire
Feb-17-15 04:00PM  Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2014 Financial Results Business Wire
Feb-12-15 09:30AM  The Zacks Analyst Blog Highlights: Achillion Pharmaceuticals, Gilead, AbbVie, Regeneron and Alkermes - Press Releases Zacks
Feb-11-15 06:00AM  Jim Cramer's Top Stock Picks: GM HAS SAVE ALKS at TheStreet
Feb-10-15 08:35PM  Jim Cramer's 'Mad Money' Recap: No Foreign News Is Great U.S. News at TheStreet
04:20PM  Alkermes Reports Positive Data on Multiple Sclerosis Drug - Analyst Blog Zacks
Feb-09-15 07:14AM  Bull targeting Alkermes on pullback optionMONSTER
07:00AM  Alkermes Announces Positive Topline Results From Phase 1 Study of ALKS 8700 for Treatment of Multiple Sclerosis Business Wire
Feb-03-15 04:00PM  Alkermes Corporate Presentation to be Webcast at Two Upcoming Conferences Business Wire
Jan-27-15 06:00PM  Cramer: Wouldn't you rather own a winner than a whiner? CNBC
Jan-19-15 09:32AM  Alkermes plc (ALKS) in Focus: Stock Moves 6.6% Higher - Tale of the Tape Zacks
Jan-14-15 02:37PM  Why Citigroup Placed An $85 Price Target On Shares Of Alkermes Benzinga
Jan-07-15 02:47PM  Schizophrenia breakthrough? CNBC +9.55%
02:19PM  Alkermes stock surges after schizophrenia drug shows effectiveness without weight gain at American City Business Journals
02:10PM  Alkermes schizophrenia drug effective without the weight gain, early data show at bizjournals.com
01:00PM  Midday movers: Alkermes, Lennar, Radian Group & more at CNBC
12:55PM  Jim Cramer Says Alkermes Shares Are Going 'Much Higher' at TheStreet
12:03PM  Alkermes Hits High On Schizophrenia Drug Results at Investor's Business Daily
10:49AM  Alkermes CEO: Our Proprietary Drug Pipeline is 'Maturing Beautifully' at TheStreet
09:55AM  Cramer's Stop Trading: 'Holy Grail' drug CNBC
09:16AM  [$$] Alkermes Schizophrenia Drug Shows Less Weight Gain at The Wall Street Journal
09:06AM  SuperValu, J.C. Penney, Monsanto climb; Micron falls at MarketWatch
08:35AM  Alkermes shares up 5% on news of positive trial for schizophrenia drug at MarketWatch
08:24AM  Alkermes schizophrenia drug meets main goal in mid-stage trial Reuters
07:00AM  Alkermes Announces Positive Results of Phase 2 Clinical Trial of ALKS 3831 in Schizophrenia Business Wire
Alkermes Public Limited Company, an integrated biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in various therapeutic areas. The company offers RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA to treat schizophrenia schizoaffective disorder; AMPYRA/FAMPYRA to treat multiple sclerosis; BYDUREON to treat type II diabetes; and VIVITROL for alcohol and opioid dependence. It is also developing Aripiprazole Lauroxil for the treatment of schizophrenia; ALKS 5461 that is under Phase III study for the treatment of depressive disorder; ALKS 3831, a Phase II study medicine to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is under Phase I study to treat multiple sclerosis; ALKS 7106, a drug candidate to treat pain with intrinsically low potential for abuse and overdose death; and RDB 1419, a proprietary investigational biologic cancer immunotherapy product that is under pre-clinical stage. The company serves pharmaceutical wholesalers, specialty pharmacies, and specialty distributors directly through its sales force. It has collaboration agreements with Janssen Pharmaceutica, NV; AstraZeneca plc; Acorda Therapeutics, Inc.; and other collaboration partners. Alkermes Public Limited Company was founded in 1987 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Jul 01Option Exercise16.5513,750227,56327,860Jul 02 05:58 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Jul 01Sale65.1313,750895,49914,110Jul 02 05:58 PM
BREYER ROBERT ADirectorJul 01Sale64.902,000129,80047,156Jul 02 05:51 PM
Cooke ShanePresident, Alkermes plcJun 23Option Exercise14.6018,000262,80058,640Jun 24 06:04 PM
Cooke ShanePresident, Alkermes plcJun 23Sale66.8418,0001,203,09840,640Jun 24 06:04 PM
MITCHELL PAUL JDirectorJun 17Option Exercise14.0415,500217,62023,500Jun 18 05:35 PM
MITCHELL PAUL JDirectorJun 17Sale65.1015,5001,009,0168,000Jun 18 05:35 PM
FRATES JAMES MSVP & CFO, Alkermes plcJun 16Option Exercise11.7410,000117,40058,713Jun 18 05:31 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Jun 16Option Exercise17.4732,977576,05647,087Jun 18 05:34 PM
FRATES JAMES MSVP & CFO, Alkermes plcJun 16Sale58.6310,000586,34948,713Jun 18 05:31 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Jun 16Sale63.1132,9772,081,24814,110Jun 18 05:34 PM
MITCHELL PAUL JDirectorJun 01Option Exercise14.041,50021,0609,500Jun 01 05:43 PM
Peterson RebeccaSVP, Corporate CommunicationsJun 01Sale60.781,983120,5270Jun 01 05:40 PM
MITCHELL PAUL JDirectorJun 01Sale60.781,50091,1708,000Jun 01 05:43 PM
BREYER ROBERT ADirectorJun 01Sale60.782,000121,56049,156Jun 01 05:45 PM
Stejbach MarkChief Commercial OfficerMay 28Option Exercise0.002,500017,453May 29 06:16 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.May 28Option Exercise0.003,000015,523May 29 06:14 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 28Option Exercise0.002,5000139,858May 29 06:11 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.May 28Option Exercise0.003,750033,069May 29 06:09 PM
Cooke ShanePresident, Alkermes plcMay 28Option Exercise0.005,750043,630May 29 06:07 PM
BIBERSTEIN KATHRYN LSVP, CLO, Secretary & CCOMay 28Option Exercise0.003,750095,002May 29 06:04 PM
Brown Iain MichaelVP, Finance & CAOMay 28Option Exercise0.001,750038,178May 29 05:33 PM
Peterson RebeccaSVP, Corporate CommunicationsMay 28Option Exercise28.4023,750674,40020,000Jun 01 05:40 PM
FRATES JAMES MSVP & CFO, Alkermes plcMay 28Option Exercise0.002,500085,115Jun 01 07:31 PM
Peterson RebeccaSVP, Corporate CommunicationsMay 28Sale59.9820,0001,199,5670Jun 01 05:40 PM
Cooke ShanePresident, Alkermes plcMay 26Option Exercise14.6018,000262,80055,880May 26 05:31 PM
Cooke ShanePresident, Alkermes plcMay 26Sale60.3118,0001,085,61537,880May 26 05:31 PM
Peterson RebeccaSVP, Corporate CommunicationsMay 26Sale60.491,32279,9680May 26 05:05 PM
Peterson RebeccaSVP, Corporate CommunicationsMay 22Sale61.111,05864,6540May 22 06:27 PM
Peterson RebeccaSVP, Corporate CommunicationsMay 21Option Exercise0.002,50002,500May 26 05:05 PM
Cooke ShanePresident, Alkermes plcMay 21Option Exercise0.005,625040,805May 22 05:42 PM
BIBERSTEIN KATHRYN LSVP, GC, Secretary, Alks, Inc.May 21Option Exercise0.004,500093,372May 22 05:39 PM
Peterson RebeccaSVP, Corporate CommunicationsMay 21Option Exercise16.5518,750310,31319,808May 22 06:27 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 21Option Exercise0.003,7500138,700May 22 06:00 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.May 21Option Exercise0.004,500031,439May 22 05:47 PM
FRATES JAMES MSVP & CFO, Alkermes plcMay 21Option Exercise0.003,750084,382May 22 05:57 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.May 21Option Exercise0.004,125014,466May 22 06:31 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 21Option Exercise0.008,1250539,471May 22 06:30 PM
Peterson RebeccaSVP, Corporate CommunicationsMay 21Sale61.6618,7501,156,0331,058May 22 06:27 PM
BIBERSTEIN KATHRYN LSVP, GC, Secretary, Alks, Inc.May 20Option Exercise0.003,750090,639May 22 05:39 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 20Option Exercise0.008,1250535,173May 22 06:30 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.May 20Option Exercise0.003,750012,108May 22 06:31 PM
Peterson RebeccaSVP, Corporate CommunicationsMay 20Option Exercise14.7410,750158,4198,750May 22 06:27 PM
FRATES JAMES MSVP & CFO, Alkermes plcMay 20Option Exercise0.003,750082,399May 22 05:57 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.May 20Option Exercise0.003,750028,706May 22 05:47 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 20Option Exercise0.003,7500136,169May 22 06:00 PM
Peterson RebeccaSVP, Corporate CommunicationsMay 20Sale61.928,750541,7610May 22 06:27 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.May 19Option Exercise16.552504,1388,608May 21 05:02 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.May 19Sale63.0025015,7518,358May 21 05:02 PM
FRATES JAMES MSVP & CFO, Alkermes plcMay 12Option Exercise11.7410,000117,40088,649May 13 06:05 PM
FRATES JAMES MSVP & CFO, Alkermes plcMay 12Sale59.3410,000593,42378,649May 13 06:05 PM
BREYER ROBERT ADirectorMay 04Sale60.002,000120,00051,156May 04 05:40 PM
MITCHELL PAUL JDirectorMay 01Option Exercise14.041,50021,0609,500May 04 06:04 PM
MITCHELL PAUL JDirectorMay 01Sale55.791,50083,6858,000May 04 06:04 PM
Cooke ShanePresident, Alkermes plcApr 23Option Exercise14.6018,000262,80053,180Apr 23 05:17 PM
Cooke ShanePresident, Alkermes plcApr 23Sale62.5518,0001,125,82135,180Apr 23 05:17 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Apr 21Option Exercise16.5525,000413,75049,956Apr 23 05:12 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Apr 21Sale62.3925,0001,559,64424,956Apr 23 05:12 PM
MITCHELL PAUL JDirectorApr 15Option Exercise14.041,50021,0609,500Apr 17 05:44 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Apr 15Option Exercise16.5513,750227,56322,108Apr 17 05:19 PM
Stejbach MarkChief Commercial OfficerApr 15Option Exercise17.305,78099,99416,544Apr 17 05:13 PM
FRATES JAMES MSVP & CFO, Alkermes plcApr 15Option Exercise9.2110,00092,10088,649Apr 17 05:28 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Apr 15Sale63.2113,750869,0848,358Apr 17 05:19 PM
FRATES JAMES MSVP & CFO, Alkermes plcApr 15Sale62.4210,000624,21878,649Apr 17 05:28 PM
MITCHELL PAUL JDirectorApr 15Sale62.711,50094,0658,000Apr 17 05:44 PM
BLOOM FLOYD EDirectorApr 06Option Exercise14.0420,000280,800110,281Apr 07 06:53 PM
BREYER ROBERT ADirectorApr 01Option Exercise14.925,00074,60058,156Apr 01 05:50 PM
BREYER ROBERT ADirectorApr 01Sale61.225,000306,10053,156Apr 01 05:50 PM
BIBERSTEIN KATHRYN LSVP, GC, Secretary, Alks, Inc.Mar 30Option Exercise18.605,37699,99486,889Apr 01 05:46 PM
Cooke ShanePresident, Alkermes plcMar 23Option Exercise14.6018,000262,80053,180Mar 24 05:15 PM
Cooke ShanePresident, Alkermes plcMar 23Sale65.3318,0001,175,92535,180Mar 24 05:15 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Mar 16Option Exercise18.1118,000325,89042,956Mar 17 05:01 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Mar 16Sale66.8118,0001,202,50424,956Mar 17 05:01 PM
FRATES JAMES MSVP & CFO, Alkermes plcMar 10Option Exercise9.2110,00092,10088,649Mar 11 05:53 PM
FRATES JAMES MSVP & CFO, Alkermes plcMar 10Sale66.2510,000662,49678,649Mar 11 05:53 PM
Peterson RebeccaSVP, Corporate CommunicationsMar 05Sale71.802,362169,5960Mar 05 05:29 PM
Stejbach MarkChief Commercial OfficerMar 03Option Exercise0.002,812011,678Mar 05 06:19 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Mar 03Option Exercise0.003,25009,889Mar 05 06:10 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 03Option Exercise0.0013,0000533,063Mar 05 06:07 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 03Option Exercise0.002,8120133,333Mar 05 05:59 PM
FRATES JAMES MSVP & CFO, Alkermes plcMar 03Option Exercise0.002,812079,974Mar 05 05:53 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Mar 03Option Exercise0.003,750026,723Mar 05 05:48 PM
Cooke ShanePresident, Alkermes plcMar 03Option Exercise0.005,250037,910Mar 05 05:42 PM
BIBERSTEIN KATHRYN LSVP, GC, Secretary, Alks, Inc.Mar 03Option Exercise0.003,500083,162Mar 05 05:37 PM
Peterson RebeccaSVP, Corporate CommunicationsMar 03Option Exercise38.4218,875725,08515,375Mar 05 05:29 PM
Peterson RebeccaSVP, Corporate CommunicationsMar 03Sale71.3115,3751,096,3720Mar 05 05:29 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Mar 02Option Exercise18.1115,000271,57521,639Mar 03 05:51 PM
BREYER ROBERT ADirectorMar 02Option Exercise14.925,00074,60058,156Mar 03 05:34 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Mar 02Sale71.3915,0001,070,9056,639Mar 03 05:51 PM
BREYER ROBERT ADirectorMar 02Sale70.865,000354,30053,156Mar 03 05:34 PM
Cooke ShanePresident, Alkermes plcFeb 23Option Exercise14.6018,000262,80050,660Feb 23 05:54 PM
Cooke ShanePresident, Alkermes plcFeb 23Sale74.2918,0001,337,30432,660Feb 23 05:54 PM
Ehrich ElliotSVP, R&D & CMO, Alkermes, Inc.Feb 17Option Exercise18.1118,000325,89040,973Feb 18 05:19 PM
Ehrich ElliotSVP, R&D & CMO, Alkermes, Inc.Feb 17Sale70.8718,0001,275,69122,973Feb 18 05:19 PM
FRATES JAMES MSVP & CFO, Alkermes plcFeb 03Option Exercise9.2110,00092,10087,162Feb 04 05:53 PM
FRATES JAMES MSVP & CFO, Alkermes plcFeb 03Sale70.8310,000708,30677,162Feb 04 05:53 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Feb 02Option Exercise18.1115,000271,57521,639Feb 04 05:49 PM
BREYER ROBERT ADirectorFeb 02Option Exercise14.925,00074,60058,156Feb 04 05:51 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Feb 02Sale72.0115,0001,080,1096,639Feb 04 05:49 PM
BREYER ROBERT ADirectorFeb 02Sale72.915,000364,55053,156Feb 04 05:51 PM